Literature DB >> 15564506

Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3.

E Stadnick1, M Dan, A Sadeghi, J K Chantler.   

Abstract

Ten antibody escape mutants of coxsackievirus B3 (CVB3) were used to identify nucleotide substitutions that determine viral virulence for the heart and pancreas. The P1 region, encoding the structural genes of each mutant, was sequenced to identify mutations associated with the lack of neutralization. Eight mutants were found to have a lysine-to arginine mutation in the puff region of VP2, while two had a glutamate-to-glycine substitution in the knob of VP3. Two mutants, EM1 and EM10, representing each of these mutations, were further analyzed, initially by determining their entire sequence. In addition to the mutations in P1, EM1 was found to have two mutations in the 3D polymerase, while EM10 had a mutation in stem-loop II of the 5' nontranslated region (5'NTR). The pathogenesis of the mutants relative to that of CVB3 strain RK [CVB3(RK)] then was examined in A/J mice. Both mutants were found to be less cardiotropic than the parental strain, with a 40-fold (EM1) or a 100- to 1,000-fold (EM10) reduction in viral titers in the heart relative to the titers of CVB3(RK). The mutations in VP2, VP3, and the 5'NTR were introduced independently into the RK infectious clone, and the phenotypes of the progeny viruses were determined. The results substantiated that the VP2 and VP3 mutations reduced cardiovirulence, while the 5'NTR mutation in EM10 was associated with a more virulent phenotype when expressed on its own. Stereographic imaging of the two mutations in the capsomer showed that they lie in close proximity on either side of a narrow cleft between the puff and the knob, forming a conformational epitope that is part of the putative binding site for coreceptor DAF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564506      PMCID: PMC533932          DOI: 10.1128/JVI.78.24.13987-14002.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  A different mode of entry by dengue-2 neutralisation escape mutant virus.

Authors:  H Y Lim; M L Ng
Journal:  Arch Virol       Date:  1999       Impact factor: 2.574

2.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

Review 3.  Genetic divergence among the group B coxsackieviruses.

Authors:  J R Romero; C Price; J J Dunn
Journal:  Curr Top Microbiol Immunol       Date:  1997       Impact factor: 4.291

4.  Cell proteins bind to multiple sites within the 5' untranslated region of poliovirus RNA.

Authors:  R M del Angel; A G Papavassiliou; C Fernández-Tomás; S J Silverstein; V R Racaniello
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 5.  Studies on the genetic basis of attenuation of the Sabin type 3 poliovirus vaccine.

Authors:  J W Almond; G D Westrop; K A Wareham; M A Skinner; D M Evans; D Magrath; G C Schild; P D Minor
Journal:  Biochem Soc Symp       Date:  1987

6.  Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor.

Authors:  Y He; P R Chipman; J Howitt; C M Bator; M A Whitt; T S Baker; R J Kuhn; C W Anderson; P Freimuth; M G Rossmann
Journal:  Nat Struct Biol       Date:  2001-10

7.  Complete nucleotide sequence of a Coxsackievirus B-4 strain capable of establishing persistent infection in human pancreatic islet cells: effects on insulin release, proinsulin synthesis, and cell morphology.

Authors:  Hong Yin; Anna-Karin Berg; Jan Westman; Claes Hellerström; Gun Frisk
Journal:  J Med Virol       Date:  2002-12       Impact factor: 2.327

8.  In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5' untranslated region of coxsackievirus B3: potential targets for antiviral action of antisense oligomers.

Authors:  D Yang; J E Wilson; D R Anderson; L Bohunek; C Cordeiro; R Kandolf; B M McManus
Journal:  Virology       Date:  1997-02-03       Impact factor: 3.616

9.  Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice.

Authors:  Bobby Yanagawa; O Brad Spiller; Jonathan Choy; Honglin Luo; Paul Cheung; Huifang M Zhang; Ian G Goodfellow; David J Evans; Agripina Suarez; Decheng Yang; Bruce M McManus
Journal:  Lab Invest       Date:  2003-01       Impact factor: 5.662

10.  Lack of islet neogenesis plays a key role in beta-cell depletion in mice infected with a diabetogenic variant of coxsackievirus B4.

Authors:  I S Yap; G Giddings; E Pocock; J K Chantler
Journal:  J Gen Virol       Date:  2003-11       Impact factor: 3.891

View more
  15 in total

1.  A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice.

Authors:  Meixia Dan; Janet K Chantler
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Molecular determinants of disease in coxsackievirus B1 murine infection.

Authors:  Javier O Cifuente; María F Ferrer; Carolina Jaquenod de Giusti; Wen-Chao Song; Víctor Romanowski; Susan L Hafenstein; Ricardo M Gómez
Journal:  J Med Virol       Date:  2011-09       Impact factor: 2.327

3.  A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.

Authors:  M Dan; J K Chantler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Intracerebral Inoculation of Mouse-Passaged Saffold Virus Type 3 Affects Cerebellar Development in Neonatal Mice.

Authors:  Osamu Kotani; Tadaki Suzuki; Masaru Yokoyama; Naoko Iwata-Yoshikawa; Noriko Nakajima; Hironori Sato; Hideki Hasegawa; Fumihiro Taguchi; Hiroyuki Shimizu; Noriyo Nagata
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

5.  The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface.

Authors:  Joshua D Yoder; Javier O Cifuente; Jieyan Pan; Jeffrey M Bergelson; Susan Hafenstein
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

Review 6.  Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

7.  Effects of the Sabin-like mutations in domain V of the internal ribosome entry segment on translational efficiency of the Coxsackievirus B3.

Authors:  Manel Ben M'hadheb-Gharbi; Jawhar Gharbi; Sylvie Paulous; Michèle Brocard; Anastasia Komaromva; Mahjoub Aouni; Katherine M Kean
Journal:  Mol Genet Genomics       Date:  2006-08-15       Impact factor: 3.291

8.  Mapping of a quantitative trait locus controlling susceptibility to Coxsackievirus B3-induced viral hepatitis.

Authors:  S A Wiltshire; J Marton; G A Leiva-Torres; S M Vidal
Journal:  Genes Immun       Date:  2015-03-19       Impact factor: 2.676

9.  Identification and typing of human enterovirus: a genomic barcode approach.

Authors:  Chengguo Wei; Guoqing Wang; Xin Chen; Honglan Huang; Bin Liu; Ying Xu; Fan Li
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

10.  Interactions between multiple genetic determinants in the 5' UTR and VP1 capsid control pathogenesis of chronic post-viral myopathy caused by coxsackievirus B1.

Authors:  Maribeth M Sandager; Jaime L Nugent; Wade L Schulz; Ronald P Messner; Patricia E Tam
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.